Literature DB >> 16210333

Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States.

Ola Landgren1, Gloria Gridley, Ingemar Turesson, Neil E Caporaso, Lynn R Goldin, Dalsu Baris, Thomas R Fears, Robert N Hoover, Martha S Linet.   

Abstract

The age-adjusted incidence of multiple myeloma (MM) is 2-fold higher in African Americans than in whites. A few small studies have reported a higher prevalence of monoclonal gammopathy of undetermined significance (MGUS) in African Americans versus whites. Etiologic factors for MGUS and determinants for transformation of MGUS to MM are unknown. We quantified the prevalence of MGUS and subsequent risk of MM among 4 million African American and white male veterans admitted to Veterans Affairs (VA) hospitals. The age-adjusted prevalence ratio of MGUS in African Americans compared with whites was 3.0 (2.7-3.3 95% confidence interval). Among 2046 MGUS cases, the estimated cumulative risk of MM during the first 10 years of follow-up was similar (P = .37) for African Americans (17%) and whites (15%). In the largest study to date, we suggest that the excess risk of MM in African Americans results from an increase in risk of MGUS rather than an increased risk of progression from MGUS to MM.

Entities:  

Mesh:

Year:  2005        PMID: 16210333      PMCID: PMC1895893          DOI: 10.1182/blood-2005-08-3449

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Frequency of pathological proteins (M-components) om 6,995 sera from an adult population.

Authors:  U Axelsson; R Bachmann; J Hällén
Journal:  Acta Med Scand       Date:  1966-02

2.  A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS.

Authors:  Wee Joo Chng; Scott A Van Wier; Gregory J Ahmann; Jerry M Winkler; Syed M Jalal; Peter Leif Bergsagel; Marta Chesi; Mike C Trendle; Martin M Oken; Emily Blood; Kim Henderson; Rafael Santana-Dávila; Robert A Kyle; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Philip R Greipp; Rafael Fonseca
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

3.  Increased incidence of monoclonal gammopathy of undetermined significance in blacks and its age-related differences with whites on the basis of a study of 397 men and one woman in a hospital setting.

Authors:  J Singh; A W Dudley; K A Kulig
Journal:  J Lab Clin Med       Date:  1990-12

4.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

5.  Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly.

Authors:  H J Cohen; J Crawford; M K Rao; C F Pieper; M S Currie
Journal:  Am J Med       Date:  1998-05       Impact factor: 4.965

Review 6.  Advances in biology of multiple myeloma: clinical applications.

Authors:  Teru Hideshima; P Leif Bergsagel; W Michael Kuehl; Kenneth C Anderson
Journal:  Blood       Date:  2004-04-15       Impact factor: 22.113

  6 in total
  109 in total

1.  A pilot program in collaboration with African American churches successfully increases awareness of the importance of cancer research and participation in cancer translational research studies among African Americans.

Authors:  Gerardo Colon-Otero; Monica Albertie; Mary Lesperance; Jennifer A Weis; Alton Coles; Nina Smith; Lynette Mills; Timothy Woodward; Alvaro Moreno Aspitia; Prakash Vishnu; Floyd Willis; Amber Isley; Rafael Fonseca; Celine Vachon; S Vincent Rajkumar
Journal:  J Cancer Educ       Date:  2012-06       Impact factor: 2.037

Review 2.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Curr Hematol Malig Rep       Date:  2010-04       Impact factor: 3.952

3.  Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women.

Authors:  Ola Landgren; S Vincent Rajkumar; Ruth M Pfeiffer; Robert A Kyle; Jerry A Katzmann; Angela Dispenzieri; Qiuyin Cai; Lynn R Goldin; Neil E Caporaso; Joseph F Fraumeni; William J Blot; Lisa B Signorello
Journal:  Blood       Date:  2010-04-26       Impact factor: 22.113

4.  Racial differences in chronic immune stimulatory conditions and risk of non-Hodgkin's lymphoma in veterans from the United States.

Authors:  Jill Koshiol; Tram Kim Lam; Gloria Gridley; David Check; Linda Morris Brown; Ola Landgren
Journal:  J Clin Oncol       Date:  2010-12-20       Impact factor: 44.544

Review 5.  Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence.

Authors:  S Vincent Rajkumar; Robert A Kyle; Francis K Buadi
Journal:  Mayo Clin Proc       Date:  2010-10       Impact factor: 7.616

6.  Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance.

Authors:  Celine M Vachon; Robert A Kyle; Terry M Therneau; Barbara J Foreman; Dirk R Larson; Colin L Colby; Tara K Phelps; Angela Dispenzieri; Shaji K Kumar; Jerry A Katzmann; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

7.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

8.  A monoclonal gammopathy precedes multiple myeloma in most patients.

Authors:  Brendan M Weiss; Jude Abadie; Pramvir Verma; Robin S Howard; W Michael Kuehl
Journal:  Blood       Date:  2009-02-20       Impact factor: 22.113

Review 9.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.

Authors:  Amit Agarwal; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2012-12-05       Impact factor: 12.531

10.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.

Authors:  Shaji K Kumar; Joseph R Mikhael; Francis K Buadi; David Dingli; Angela Dispenzieri; Rafael Fonseca; Morie A Gertz; Philip R Greipp; Suzanne R Hayman; Robert A Kyle; Martha Q Lacy; John A Lust; Craig B Reeder; Vivek Roy; Stephen J Russell; Kristen E Detweiler Short; A Keith Stewart; Thomas E Witzig; Steven R Zeldenrust; Robert J Dalton; S Vincent Rajkumar; P Leif Bergsagel
Journal:  Mayo Clin Proc       Date:  2009-12       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.